Company profile
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sodium phenylbutyrate | approved | — | 0 | — |
| TAURURSODIOL | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04516096 | phase2_3 | completed | 2020-11-22 | 2022-12-30 | Amylyx Pharmaceuticals Inc. | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) |
| NCT06122662 | phase2_3 | completed | 2023-12-21 | 2025-09-30 | Amylyx Pharmaceuticals Inc. | AMX0035 and Progressive Supranuclear Palsy |
| NCT05676034 | phase2 | active_not_recruiting | 2023-03-03 | 2024-07-23 | Amylyx Pharmaceuticals Inc. | AMX0035 in Adult Patients With Wolfram Syndrome |
| NCT03127514 | phase2 | completed | 2017-06-22 | 2019-09-25 | Amylyx Pharmaceuticals Inc. | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| NCT06665165 | phase1 | recruiting | 2025-04-07 | 2027-02-01 | Amylyx Pharmaceuticals Inc. | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 216660 | NDA | AMYLYX PHARMACEUTICALS INC | ||||
Loading… | ||||||